Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511326 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4EPRMT5 | |
| SCHEMBL31391337 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4EPRMT5 | |
| SCHEMBL13305067 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP3A4MAPTKDM4EPRMT5 | |
| SCHEMBL30523855 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL9961325 | 0.75 | LMNA (0.37) | ALDH1A1MAPTCYP1A2CCR1CCR5 | |
| SCHEMBL11024480 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL3952706 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL41713 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4EPRMT5 | |
| SCHEMBL31029246 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4ENPC1 | |
| SCHEMBL15638042 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119075-A | Targeting protein degradation agent with artemisinin analogue as hydrophobic tag and preparation method and application thereof | 贵州大学 | 2024-12-13 | — | — | CN | disclosed |
| US-20240350496-A1 | Design, Synthesis, and Structure-Activity Relationships of Substituted Pyrido[3,2-d]Pyrimidines as Microtubule Targeting Agents and Anti-Cancer Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2024-10-24 | — | — | US | disclosed |
| CN-118696042-A | Crystalline forms of allyl-containing methylpyridinopyrimidine compounds | 南京明德新药研发有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118696042-A | Crystalline forms of allyl-containing methylpyridinopyrimidine compounds | 南京明德新药研发有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023138526-A1 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | 南京明德新药研发有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138526-A1 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | 南京明德新药研发有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-10-03 | — | — | US | disclosed |
| EP-2514749-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120206037-A1 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD (KR) | 2012-08-16 | — | — | US | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011074560-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | 塩野義製薬株式会社 (JP) | 2011-06-23 | — | — | WO | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1491541-B1 | Pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120206037-A1 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | OCIAD1, OCIAD2, OSBPL8 | ALDH1A1 1119/4885CYP3A4 1192/4885MAPT 1430/4885 |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, LPL, CEL | ALDH1A1 2861/4885CYP3A4 1304/4885MAPT 4884/4885 |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | ALDH1A1 240/4885CYP3A4 3775/4885MAPT 2998/4885 |
| US-20240350496-A1 | Design, Synthesis, and Structure-Activity Relationships of Substituted Pyrido[3,2-d]Pyrimidines as Microtubule Targeting Agents and Anti-Cancer Agents | MAP2, TUBB6, TUBB1 | ALDH1A1 1800/4885CYP3A4 1709/4885MAPT 29/4885 |
| US-20130261140-A1 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP7, DPP3 | ALDH1A1 809/4885CYP3A4 82/4885MAPT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.